quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·527d
PRRelease
Aileron Therapeutics Inc. logo

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

ALRN· Aileron Therapeutics Inc.
Health Care
Original source

Companies

  • ALRN
    Aileron Therapeutics Inc.
    Health Care

Related

  • SEC468d
    SEC Form 8-K filed by Aileron Therapeutics Inc.
  • PR468d
    Aileron Therapeutics Announces Rebranding to Rein Therapeutics
  • INSIDER500d
    President and CEO Windsor James Brian bought $898 worth of shares (400 units at $2.24) (SEC Form 4)
  • INSIDER503d
    SEC Form 4 filed by Director Aivado Manuel
  • INSIDER503d
    SEC Form 4 filed by Director Ambros Reinhard J.
  • INSIDER503d
    SEC Form 4 filed by Director Fairey William
  • INSIDER503d
    SEC Form 4 filed by Director Von Rickenbach Josef H
  • INSIDER503d
    SEC Form 4 filed by Director Musso Alan A
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022